#ASCO22: With median durability data, Cullinan aims to 'distinguish itself' from Takeda's Exkivity and J&J's Rybrevant in exon 20 NSCLC
CHICAGO — In its “first time on a bigger stage” at this weekend’s ASCO conference, Cullinan Oncology thinks it has the data to “distinguish itself” from the only other approved drugs for EGFR exon 20 insertion mutations, which are found in about 2% to 3% of patients with non-small cell lung cancer, CMO Jeff Jones tells Endpoints News.
Those are Takeda’s Exkivity and Johnson & Johnson’s Rybrevant, both greenlit last year. While those Big Pharmas might have crossed the finish line first, Cullinan says its drug is better in terms of durability of response, and that’s likely attributed to a relatively better tolerability profile, Jones said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
